
MEDVi Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.1/10
Best for: switching between compounded and brand-name GLP-1 through one provider
MEDVi scores below our bar on medical oversight. Read the score breakdown before signing up.
Semaglutide
then $199/mo ongoing
Price checked on MEDVi’s site,
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not stated
Coaching
Included
No insurance needed · Vetted by our editors
PartnerMEDVi is a partner: we may earn a commission if you sign up through our links. It doesn't affect the score. How we make money
MEDVi is a telehealth weight-loss platform offering compounded GLP-1 injections and tablets (semaglutide) as well as brand-name Wegovy and Zepbound through licensed US pharmacies. Medical treatment is delivered by OpenLoop Health clinicians and CareGLP Affiliated P.C.s.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
What is MEDVi?
MEDVi is an online weight-loss program where licensed clinicians from the OpenLoop Health network can prescribe GLP-1 medication after an online visit. It leads with compounded semaglutide as a weekly injection or a daily dissolvable tablet, and it also offers brand-name Wegovy and Zepbound through a separate membership. It suits people who want to start quickly with a cash-pay plan and have the option to move to a brand-name drug later.
MEDVi at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide, Wegovy, Zepbound
- Starting price
- $199/mo (after intro offer) ($99 first month; 'Refills are locked in at $199'; the first month is $99 during MEDVi's 'FALL Sale'.)
- What's included
- Medication · Consult · Shipping · Coaching
- Availability
- 48 states
- FDA status
- 1 FDA warning letter on record; see below
How we scored MEDVi
Each dimension is scored algorithmically from MEDVi’s published pricing, drugs offered, verification status, and disclosed inclusions, using the same six-dimension framework we apply to every provider.
Value25%
6.5/10At $199/mo (after intro offer), MEDVi runs about 11% above the $179 median for GLP-1 providers (each program's lowest listed ongoing monthly price for compounded semaglutide), with an intro price of $99.
Effectiveness25%
8.2/10MEDVi offers both semaglutide and tirzepatide, the two GLP-1 molecules with the strongest published weight-loss trial outcomes. FDA-approved brand options are available alongside compounded versions. An oral/needle-free option is offered for patients who avoid injections.
User Experience15%
7.1/10Online intake and platform experience (consult included in the price); 7 platform features disclosed.
Trust & Safety15%
5.5/10Core details confirmed by our editors; an FDA warning letter is on file (see flag above); discloses which pharmacy makes its medication.
Accessibility10%
8.0/10MEDVi is available in 48 states: all but Mississippi, North Dakota.
Support10%
6.9/10Coaching/dietitian access included.
Each checked against the provider’s own site.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this MEDVi review
Last checked November 2026- Confirmed current pricing across 2 dose/plan tiers and 2 separate fees
- Confirmed availability in 48 states
- Confirmed what the monthly price does and doesn't include
- Verified the compounding pharmacy partner
- Checked the FDA warning-letter database for enforcement actions
- Walked the provider's public sign-up flow, stopping before payment
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records. See the sources below. Editorial confidence in this data: medium.
What we checked
- Provider's own pricing page
- $199–$249/mo across 2 dose/plan tiers, plus 2 $99/mo fees that exclude the medication (checked November 2026)
- FDA warning-letter register
- An active letter is on file for this provider; see below
- Compounding pharmacy partners
- Triad Rx, RedRock Pharmacy, Beaker Pharmacy & Compounding
What to expect when you sign up with MEDVi
We walked MEDVi’s public signup flow in July 2026 to document the process (the steps, pricing transparency, and what’s required) before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Medical intake questionnaire: you report your health history, goals, and current weight online.
- 2Checkout: you select a plan and pay before the eligibility consult (MedVi's clinician review happens after checkout).
- 3Telehealth consultation: an OpenLoop Health licensed clinician reviews your intake and medical history and decides whether a compounded GLP-1 is appropriate.
- 4If approved, the prescription ships from the pharmacy to your door; you re-report weight every 3-4 weeks for ongoing care.
- Pricing is shown up front (compounded injections $99 for the first month, then $199) before you fill out intake. It's a flat monthly cash price rather than a dose-by-dose breakdown.
- You pay at checkout before the clinician confirms you qualify. MedVi's site says you're refunded if you're found ineligible, but the charge comes first.
- It's async telehealth (questionnaire + clinician review), so no baseline labs or live video visit are required. That makes it faster to start than lab-gated providers, with a lighter clinical touch.
- Cash-pay only; MedVi notes your insurance may reimburse you for branded options. The plan bundles a personalized plan, 1:1 guidance, a metabolic report, and the medication.
- Care is delivered by OpenLoop Health clinicians, a named, established telehealth clinician network, and they retain the prescribing decision.
GLP-1 medications MEDVi offers
Tap any medication to read our plain-English guide: how it works, dosing, side effects, and what the trials found.
Pricing
Prices re-verified
'Refills are locked in at $199'; the first month is $99 during MEDVi's 'FALL Sale'.
Flat price: 'Starting at $249'. No intro discount is shown.
$99 membership plus the medication cost, which MEDVi does not publish (it varies, and insurance may reimburse). 'Availability is subject to change.'
$99 membership plus the medication cost, which MEDVi does not publish.
Ready to get started?
Plans and promotions change often, so check MEDVi's current pricing and active discounts before you decide.
MEDVi compounding-pharmacy partners
Each partner below is a 503A or 503B pharmacy that MEDVi routes prescriptions through.
What we like
- Both compounded and brand-name (Wegovy, Zepbound) GLP-1 options in one platform
- Oral tablet and injectable formats
- Named US pharmacy partners (Triad Rx, RedRock Pharmacy, Beaker Pharmacy & Compounding)
- Clinical oversight through OpenLoop Health provider network and CareGLP Affiliated P.C.s
- Direct-to-home shipping with 24/7 support
Watch-outs
- Refill price for the compounded GLP-1 injection ($199) is double the $99 first-month offer
- Not available in Mississippi or North Dakota (telehealth regulation constraints)
- Alabama and California patients can only receive injectable formats, not tablets, per state law
- Kansas, Indiana, New Mexico, Oklahoma, and West Virginia require a synchronous provider visit before prescribing
- You pay at checkout before a clinician confirms you qualify, and monthly plans aren't refunded once the month has started
MEDVi at a glance: one platform, both compounded and brand-name GLP-1
Most GLP-1 telehealth services pick a lane: they either sell cheaper compounded medication or they route you toward brand-name Wegovy and Zepbound. MEDVi is built around the opposite idea. It lets you start on lower-cost compounded semaglutide and, if you'd rather move to an FDA-approved branded drug, switch to Wegovy or Zepbound (tirzepatide) without leaving the platform or rebuilding your care from scratch. If you don't know yet whether you want to stay compounded for the savings or graduate to a name-brand pen, that flexibility is the single best reason to consider MEDVi.
The flip side is that MEDVi says little about its pharmacies' accreditation, and the price you see in month one is not the price you keep paying. Both points matter, and we cover them below.
How MEDVi's pricing works
MEDVi runs two different pricing structures depending on whether you choose compounded or brand-name medication, and confusing the two is the easiest way to be surprised by your bill.
On the compounded side, the medication is bundled into one program fee. Your monthly cost covers the physician review, your personalized plan, 1:1 guidance, a metabolic report, and the prescription shipped to your door. There's no separate charge for the drug itself. The introductory rate of $99 for the first month of compounded GLP-1 injection is the headline you'll see, but refills are $199 a month after that, so the first-month figure is a teaser, not your ongoing cost. Compounded tablets sit at their own higher tier, starting at $249 a month. For context, the category median is $179, and the post-promo refill is what you should budget around.
How we get the market median: $179 is the middle value of each program's lowest listed ongoing monthly price for compounded semaglutide (month to month, not a first-month promo, a prepaid plan or a price with a membership on top), across the 121 programs that publish one.
Brand-name Wegovy and Zepbound work differently: those run on a membership-plus-medication model, where you pay a monthly membership and then the cost of the branded drug on top. That can be the right choice if you want the exact FDA-approved product, but it is a meaningfully different (and usually pricier) commitment than the all-in compounded program.
What you're paying for
- Compounded program: one bundled fee that includes the medication, clinician review, shipping, and coaching
- Brand program: an approximately ninety-nine-dollar membership fee plus the separate cost of Wegovy or Zepbound
- Included with both: free shipping, no insurance required, and free dietitian visits and care coaching
The medications and who dispenses them
MEDVi offers compounded semaglutide as both an injection and an oral tablet, plus brand-name Wegovy (pill or injection) and Zepbound. The oral tablet option is useful for needle-averse patients (not every provider offers a swallowable semaglutide), though Alabama and California patients are limited to injectables only because of state law.
Where MEDVi earns some credit is transparency about its supply chain. Rather than hiding behind a vague 'licensed pharmacy partner,' the company names the three compounding pharmacies it works with: Triad Rx in Daphne, Alabama; RedRock Pharmacy in St. George, Utah; and Beaker Pharmacy & Compounding in McKinney, Texas. The medical side is handled by the OpenLoop Health clinician network and CareGLP Affiliated P.C.s. Naming locatable US pharmacies and a known telehealth provider group is more disclosure than many compounded-GLP-1 sites offer.
The differentiator: switchability without starting over
The reason to choose MEDVi over a cheaper compounded-only service is optionality. You can begin on compounded semaglutide to control costs, then move to brand-name Zepbound if your insurance situation changes, if supply tightens, or if you simply decide you want the FDA-approved product. It all stays under one account, one clinical record, and one coaching relationship. For people who are still deciding what they want long-term, that removes the friction of switching providers mid-journey, which is a specific, practical advantage.
Where MEDVi falls short
Two things should give you pause. First, the accreditation gap: MEDVi displays a LegitScript seal, but it doesn't publish PCAB or other accreditation for its compounding pharmacies. That doesn't mean they are unaccredited, but for a compounded-medication service it is a fair reason to ask questions before you commit. Second, the price step-up: the attractive first-month compounded injection rate rises from $99 to $199 at refill, so anyone shopping purely on that opening number is likely to feel the increase by month two.
- No published PCAB accreditation for its pharmacies, so confirm accreditation directly before ordering
- Refill pricing jumps well above the first-month compounded injection offer
- Not available in [Mississippi](/states/mississippi) or [North Dakota](/states/north-dakota) due to telehealth rules
- Alabama and California are injectable-only, no tablets
- Kansas, Indiana, New Mexico, Oklahoma, and West Virginia require a live provider visit before prescribing
Who should choose MEDVi, and who should skip it
Choose MEDVi if you value the freedom to move between compounded and brand-name GLP-1 within one platform, if you want an oral tablet option, and if a bundled program fee with included coaching and free shipping fits how you like to pay. It covers 48 states, so most US patients can access it.
Skip it if you want a service that leads with its accreditations (one that does is Ivologist, which holds a LegitScript certification and serves all 50 states), or if you're optimizing purely for the lowest long-term compounded price (the refill rate isn't the cheapest around). Skip it too if you live in a state with the synchronous-visit requirement and want a fully asynchronous experience. Compare its ongoing cost against the $179 category median using our scoring methodology before you lock in.
Bottom line
MEDVi is a solid pick for the specific patient who wants a single home for both compounded and brand-name GLP-1 and the ability to switch between them. The pharmacy and clinician disclosure is better than average, and the compounded program's all-in pricing is convenient. Go in with eyes open on two fronts: the refill price is the number that matters, not the first-month teaser, and the lack of published pharmacy accreditation deserves a direct question before you hand over a card. Treat it as a flexible, mid-priced option (not the cheapest, and not the most credential-forward) and it can be a smart fit.
The Bottom Line
MEDVi scores below our bar on medical oversight. Read the score breakdown before signing up.
Ready to start with MEDVi?
From $199/mo (after intro offer). See current pricing and start your free consultation.
Alternatives to MEDVi
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Collective
Best for: the lowest flat medication price if you can absorb an annual membership fee
Editorial score · methodology
CoreAge Rx
Best for: lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Editorial score · methodology
Head-to-head
Compare MEDVi vs…
MEDVi scores7.1/10
Side-by-side pricing, medications and scores. Pick a matchup.
MEDVi vs Amazon One Medical
Amazon One Medical scores 8.5/10

MEDVi vs Vytora Health
Vytora Health scores 8.4/10

MEDVi vs CoreAge Rx
CoreAge Rx scores 8.3/10

MEDVi vs Collective
Collective scores 8.3/10

MEDVi vs Found
Found scores 8.3/10
MEDVi vs EverSlim
EverSlim scores 8.3/10
All 45 MEDVi comparisons
- MEDVi vs AgelessRx
- MEDVi vs altRX
- MEDVi vs Belle Health
- MEDVi vs bmiMD
- MEDVi vs Bodybuilding Health+
- MEDVi vs Brightmeds
- MEDVi vs Direct Meds
- MEDVi vs DudeMeds
- MEDVi vs Eden
- MEDVi vs Embody
- MEDVi vs Enhance MD
- MEDVi vs Gala
- MEDVi vs GobyMeds
- MEDVi vs HealthRX
- MEDVi vs HumeCare+
- MEDVi vs Ivim Health
- MEDVi vs Live Vital
- MEDVi vs Lttl
- MEDVi vs Luvo Health
- MEDVi vs MadeMed
- MEDVi vs MangoRx
- MEDVi vs Maximus
- MEDVi vs MEDGm
- MEDVi vs Midi Health
- MEDVi vs NewSelf
- MEDVi vs Oak
- MEDVi vs PlexusDx
- MEDVi vs Ro
- MEDVi vs RxSpan MD
- MEDVi vs Sesame Care
- MEDVi vs ShedRx
- MEDVi vs SkinnyRx
- MEDVi vs SnagRx
- MEDVi vs Sprout Health
- MEDVi vs Strut Health
- MEDVi vs TMates
- MEDVi vs TrimRx
- MEDVi vs Wellorithm
- MEDVi vs YourEra
Scores are our independent editorial ratings out of 10.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
MEDVi received an FDA warning letter dated February 20, 2026
The letter concerns false & misleading claims/misbranded. FDA warning letters are public regulatory communications and do not, on their own, constitute a finding of illegal activity. Companies often respond with corrective action.
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this MEDVi review:
Sources & methodology (as of November 2026)
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See MEDVi's current pricing
Plans from $199/mo (after intro offer). Start your free consultation to check eligibility and today's price.